title: Comparing new anticoagulants.
abstract: For years, the pharmaceutical industry has been trying to find a safe and effective drug to replace warfarin. Although warfarin is an effective anticoagulant, its pharmacology, adverse effects, and risk profiles dictate that patients taking this medication must be monitored judiciously. The US Food and Drug Administration has approved two drugs for commercial use, dabigatran and rivaroxaban, that will compete directly with warfarin for use in specific indications. Because of direct marketing to patients, physicians are being asked to comment on these new medications. This brief review illustrates the data available for the two new drugs when compared to warfarin for the specified indications. For some patients, these drugs may be highly beneficial and offer an excellent alternative to warfarin. For others, warfarin may still be the preferred drug.
authors.affiliation: University of Missouri-Kansas City School of Medicine, Kansas City, MO 64108, USA. wootenj@umkc.edu
authors.forename: James M
authors.initials: JM
authors.lastname: Wooten
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology*; D000991:Antithrombins / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000494:pharmacology*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000494:pharmacology*; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000494:pharmacology*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran